IP Verse

Tablet Formulation Comprising A Peptide And A Delivery Agent

Patent No. EP2863895 (titled "Tablet Formulation Comprising A Peptide And A Delivery Agent") was filed by Novo Nordisk on Jun 19, 2013. The application was issued on Apr 14, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (8)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
CMS CAMERON MCKENNA NABARRO OLSWANGJan 14, 2022-
GALENICUM HEALTH SLUJan 14, 2022-
KRKAJan 14, 2022HOFFMANN EITLE
SANDOZJan 14, 2022MAIWALD
GENERICS UKJan 13, 2022TER MEER STEINMEISTER & PARTNER
MERCK SHARP & DOHMEJan 13, 2022HUSSAIN
TEVA PHARMACEUTICALSJan 11, 2022LEDERER & KELLER
TEVA PHARMACEUTICALSJan 11, 2022LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2863895

NOVO NORDISK
Application Number
EP13729743A
Filing Date
Jun 19, 2013
Status
Revoked
Oct 21, 2022
Publication Date
Apr 14, 2021
External Links
Slate, Register , Google Patents